How Much Does Evenity (Romosozumab) Cost in Vermont in 2026?

Vermont Retail Price for Evenity in 2026

The average cash-pay price for Evenity across Vermont retail pharmacies sits at $1,825 per monthly dose in 2026, matching Amgen's wholesale acquisition cost. A full 12-month course runs approximately $21,900 before any insurance or discount program. This price reflects the two prefilled syringes (each containing 105 mg, totaling a 210 mg dose) administered subcutaneously once per month as specified in the FDA-approved prescribing information.

Romosozumab is a first-in-class monoclonal antibody that inhibits sclerostin, a protein that blocks bone formation. The FRAME trial (N=7,180) demonstrated that romosozumab reduced new vertebral fracture risk by 73% compared to placebo at 12 months. Given these outcomes, many payers view the drug's price as justified for patients with high fracture risk, though the cost still represents a significant financial burden for uninsured or underinsured Vermonters. Price variation between Vermont pharmacies is minimal because the drug is a branded biologic with a single manufacturer. Specialty pharmacies may offer marginally different dispensing fees, but the drug cost itself is fixed.

Vermont Medicaid Coverage for Romosozumab

Vermont Medicaid covers Evenity with prior authorization for severe osteoporosis. The PA process typically requires documentation of a T-score of -2.5 or below on DXA scan at the hip or spine, a history of osteoporotic fracture, or failure of first-line antiresorptive therapy such as alendronate or zoledronic acid. The Endocrine Society's 2020 clinical practice guideline recommends anabolic agents like romosozumab as initial therapy for patients at very high fracture risk, a recommendation that strengthens PA approval odds.

Vermont's Medicaid preferred drug list generally requires step therapy through an oral bisphosphonate before approving romosozumab. Prescribers should submit clinical notes showing bisphosphonate intolerance, contraindication, or inadequate response. Approval windows are typically 12 months, matching the recommended treatment duration. For patients with a recent fragility fracture, especially vertebral or hip, approval rates tend to be higher because the ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced new vertebral fracture risk by 48% compared to alendronate alone at 24 months.

Medicaid recipients should expect the PA process to take 5 to 15 business days. Denials can be appealed through Vermont's fair hearing process, and the prescribing clinician's letter of medical necessity carries substantial weight in appeals.

Commercial Insurance Coverage in Vermont

Most major commercial insurers operating in Vermont, including Blue Cross Blue Shield of Vermont, MVP Health Care, and Cigna, cover Evenity on their specialty pharmacy tier with prior authorization. Formulary placement varies by plan year, but the drug typically sits on Tier 4 or Tier 5, resulting in coinsurance of 20% to 40% before reaching the out-of-pocket maximum.

The American Association of Clinical Endocrinology 2020 guidelines classify romosozumab as appropriate first-line therapy for patients with very high fracture risk (defined as a recent fracture within the past 12 months, fractures while on approved osteoporosis therapy, multiple fractures, T-score below -3.0, or high FRAX probability). Citing these guidelines in the PA request increases the likelihood of first-pass approval.

A 2020 cost-effectiveness analysis published in the Journal of Bone and Mineral Research found romosozumab-to-alendronate was cost-effective at a $150,000-per-QALY threshold for women aged 70 and older with T-scores at or below -2.5 and a prior fracture. Insurers increasingly recognize this data. Patients who have already fractured while taking a bisphosphonate present the strongest case for coverage.

For commercially insured patients facing high coinsurance, the Amgen Assist 360 program (discussed below) can eliminate most or all out-of-pocket cost.

How the Amgen Assist 360 Savings Card Works

Amgen's patient support program, Assist 360, offers a copay savings card that can reduce out-of-pocket costs for commercially insured patients to as little as $0 per dose. The card is accepted at most Vermont specialty pharmacies. Eligibility requirements include having commercial insurance (not Medicare, Medicaid, or other government plans) and a valid prescription for Evenity.

Patients can enroll by calling Amgen Assist 360 at 1-833-EVENITY or through their prescribing provider's office. The program also connects patients with nurse ambassadors, injection training resources, and benefits verification support. Amgen reports that the majority of commercially insured patients using the card pay $5 or less per month. The savings card covers up to a program-specified maximum annual benefit; patients should confirm the current cap with Amgen directly, as benefit limits can change by plan year.

For Medicare Part B beneficiaries, Evenity administered in a provider's office may be covered under the medical benefit rather than the pharmacy benefit, with the patient responsible for the 20% coinsurance after the deductible. Medicare Supplement (Medigap) plans may cover part or all of that coinsurance. The Amgen Safety Net Foundation offers free Evenity to patients who meet income eligibility requirements and lack adequate coverage.

Compounded Romosozumab in Vermont

Licensed 503A compounding pharmacies in Vermont can legally compound romosozumab preparations. Section 503A of the Federal Food, Drug, and Cosmetic Act permits patient-specific compounding by state-licensed pharmacies operating under a valid prescription. Vermont does not impose additional state-level restrictions beyond federal 503A requirements.

Several important caveats apply. Compounded romosozumab is not FDA-approved and has not undergone the same bioequivalence testing as Amgen's branded Evenity. The FDA's guidance on compounding makes clear that compounded drugs are not evaluated for safety, efficacy, or manufacturing consistency in the same manner as approved drugs. Patients considering a compounded version should discuss the tradeoffs with their prescriber, particularly regarding potency assurance and sterility standards.

Compounded preparations may cost significantly less than the branded product, though exact pricing varies by pharmacy and is not standardized. Patients should verify that any 503A pharmacy they use holds a current Vermont Board of Pharmacy license and follows USP 797 sterile compounding standards.

Telehealth Prescribing of Evenity in Vermont

Vermont permits telehealth prescribing of Evenity. The state's telehealth parity law requires insurers to cover telehealth-delivered services at the same rate as in-person visits, meaning the initial osteoporosis evaluation, DXA scan review, and romosozumab prescription can all be handled via video visit with a Vermont-licensed provider. The prescriber must document the clinical rationale for romosozumab per the FDA's boxed warning regarding cardiovascular risk, which limits use to patients without a myocardial infarction or stroke within the preceding year.

After the telehealth visit, the prescription is typically routed to a specialty pharmacy for home delivery or to the patient's local infusion provider. Patients self-administer the subcutaneous injection at home using prefilled syringes. Training can be provided virtually. Follow-up bone density monitoring and labs can be coordinated through the same telehealth platform, with DXA scans performed at a local imaging center.

Reducing Your Out-of-Pocket Cost: A Step-by-Step Approach

Start with insurance verification. Contact your insurer's specialty pharmacy line and request a benefits investigation for Evenity (NDC 55513-0861-02). Ask specifically whether your plan covers romosozumab, what tier it occupies, and whether step therapy through a bisphosphonate is required.

If you have commercial insurance, enroll in the Amgen Assist 360 program before filling the prescription. The savings card can be applied at the point of sale. If you are uninsured or underinsured, ask about the Amgen Safety Net Foundation, which provides Evenity at no cost to qualifying patients.

For Vermont Medicaid recipients, the prescriber should submit the PA with the ARCH trial data and relevant guideline citations, particularly for patients with a FRAX 10-year major osteoporotic fracture probability exceeding 20% or a hip fracture probability exceeding 3%, thresholds supported by the National Osteoporosis Foundation's Clinician's Guide.

Patients who are denied coverage should request a peer-to-peer review between the insurer's medical director and the prescribing physician. Data from the FRAME extension study showing sustained fracture risk reduction with sequential romosozumab-to-denosumab therapy can support appeals for patients with very severe disease.

Cardiovascular Safety and Prescribing Considerations

Evenity carries an FDA boxed warning for potential increased risk of myocardial infarction, stroke, and cardiovascular death. This warning stems from the ARCH trial, which found a numerically higher rate of adjudicated major adverse cardiovascular events in the romosozumab group (2.5%) compared to the alendronate group (1.9%) during the first 12 months. The difference was primarily driven by cardiac ischemic events.

Prescribers in Vermont should screen patients for cardiovascular risk factors before initiating therapy. Romosozumab should not be prescribed to patients who have had a myocardial infarction or stroke within the past year. The 2020 AACE/ACE guideline update advises that patients with high cardiovascular risk may be better candidates for teriparatide or abaloparatide, both of which carry anabolic bone-forming properties without the same cardiovascular signal.

Vermont patients over age 70 with established cardiovascular disease should have a documented risk-benefit discussion in the medical record before starting romosozumab.

How Romosozumab Compares to Other Osteoporosis Drugs on Cost

Teriparatide (Forteo) carries a list price of approximately $3,600 per month for daily subcutaneous injections over 24 months, making the total course cost roughly $86,400. Abaloparatide (Tymlos) runs about $3,200 per month for 18 to 24 months. Denosumab (Prolia) costs approximately $1,800 per dose given every 6 months. Oral alendronate, the first-line generic bisphosphonate, costs $10 to $30 per month.

Romosozumab's 12-month treatment window is shorter than teriparatide's 24-month course, which reduces total drug exposure and cumulative cost. A 2021 network meta-analysis found romosozumab produced the largest gains in lumbar spine BMD at 12 months among all approved osteoporosis therapies, with a weighted mean difference of approximately 13% over baseline. This rapid BMD accrual may justify the monthly cost for patients who need fast skeletal stabilization, particularly those with recent vertebral compression fractures.

Sequential therapy matters. The key trials all transitioned patients to an antiresorptive agent (denosumab or alendronate) after completing 12 months of romosozumab. Stopping romosozumab without starting a follow-on antiresorptive leads to BMD loss within 12 months. Clinicians should factor the cost of the follow-on drug into the total treatment plan when counseling patients.